Monte Rosa outlines 2024 milestones: Fast Track for MRT-2359, MRT-6160 Phase 1, cash into H1 2026

Monte Rosa Therapeutics, Inc.

FDA Fast Track Designation for MRT-2359 in previously treated metastatic SCLC with L-MYC or N-MYC expression.
RP2D for MRT-2359 Phase 1/2 trial in MYC-driven solid tumors expected Q2 2024; new dose schedule initiated.
MRT-6160 (VAV1-directed MGD) IND submission H1 2024, Phase 1 SAD/MAD study in healthy volunteers mid-2024.
Cash runway into H1 2026; NEK7 development candidate nomination Q1 2024, CDK2 candidate in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.